Rating Rationale
September 02, 2022 | Mumbai
Biocon Limited
Long term rating continues on 'Watch Developing'; Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities RatedRs.250 Crore
Long Term RatingCRISIL AA+/Watch Developing (Continues on 'Rating Watch with Developing Implications')
Short Term RatingCRISIL A1+ (Reaffirmed)
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings’ rating on the long term bank facilities of Biocon Ltd (Biocon) continue on 'Rating Watch with Developing Implications’. and has reaffirmed the 'CRISIL A1+' rating on the short-term bank facilities.

 

CRISIL Ratings had placed its long-term rating on watch with developing implications in March 2022, following announcement by Biocon Biologics Ltd (BBL, subsidiary of Biocon) that its Board of Directors, at a meeting held on February 27, 2022, approved the proposed acquisition of the biosimilar business of US-based Viatris Inc. Accordingly, BBL entered into a definitive agreement with Viatris Inc to acquire its biosimilars business for a total consideration of USD 3.335 billion, including cash up to USD 2.335 billion and compulsorily convertible preference shares (CCPS) in BBL of USD 1 billion. The upfront cash payment of USD 2 billion is expected to be funded by ~USD 800 million raised through equity infusion in BBL by certain existing investors including Biocon and Serum Institute of India and the remainder is to be funded by debt for which the company has commitment letters from certain foreign banks. The transaction is expected to close in the second half of calendar year 2022, subject to satisfaction of closing conditions and certain regulatory approvals.

 

CRISIL Ratings will continue to monitor progress on the transaction and will remove the ratings from watch and take a final rating action once the regulatory approvals are in place and the transaction is concluded. While this transaction will enable BBL to attain commercialisation expertise in the developed markets and realize the higher revenue and associated profits from its partnered products, its debt protection metrics could moderate in the near-term due to the large debt expected to be taken for the acquisition. Nonetheless, CRISIL Ratings expects the debt protection metrics to improve back to almost current-levels by fiscal 2024.

 

CRISIL Ratings will remain in discussion with BBL’s management to better understand the terms of debt funding for the transaction as well as the synergy benefits that may emerge post completion of the transaction. CRISIL Ratings also notes that the company may undertake an initial public offering (IPO) over the next two years depending on the market conditions.

 

Earlier, in September 2021, BBL and Serum Institute Life Sciences Pvt Ltd (SILS), announced a strategic alliance as part of which BBL will offer around 15% stake to SILS at a post-money valuation of around USD 4.9 billion, for which it will get committed access to 100 million doses of vaccines per annum for 15 years. This alliance received approval from the competition commission of India (CCI) in May 2022 and is subject to other regulatory approvals and is on track to be implemented by October 1, 2022. CRISIL Ratings expects this alliance to strengthen BBL’s business risk profile and product offerings over the medium term and will continue to monitor the developments in this regard.

 

The ratings continue to reflect the established market position of Biocon in the biopharmaceutical (biopharma) segment, its diversified revenue profile and healthy pipeline of biosimilar products. The ratings also factor in strong financial risk profile driven by healthy debt protection metrics. These strengths are partially offset by uncertainty regarding payoffs in the research and development (R&D)-driven model for development and commercialisation of biosimilars and novel molecules and susceptibility to regulatory uncertainties and intense competition.

Analytical Approach

CRISIL Ratings has combined the business and financial risk profiles of Biocon and its subsidiaries as all the companies, collectively referred to herein as Biocon, operate in the biopharma sector and have common management. The joint venture, Neo Biocon FZ-LLC, has been moderately consolidated. CRISIL Ratings has amortised goodwill on acquisition and intangibles (including products under development) over five years.

 

Please refer Annexure - List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description

Strengths:

  • Established position in the biopharma segment

Biocon is a leading biopharma company in India and has track record of 40 years. In the biopharma segment, the company has presence primarily in India and semi-regulated economies. In the domestic formulations market, it is a biosimilars-focused specialty products company, mainly in chronic therapy areas. The domestic business has multiple divisions such as metabolics, oncology, nephrology, immunotherapy and comprehensive care. The company has strong brands such as Insugen® (rh-insulin), BASALOG™ (insulin glargine), BIOMab-EFGR® (nimotuzumab), BLISTO® (glimepiride + metformin), CANMab (trastuzumab), KABEVA (bevacizumab), Evertor® (everolimus), TACROGRAF™ (tacrolimus), and ALZUMAb™ (itolizumab) across its biosimilars and novel biologics portfolio. It is among the leading players in insulin in Asia, with its global capacities making it a leading insulin producer globally. Biocon also is a leading supplier of complex, small molecule active pharmaceutical ingredients (APIs) across the cardiovascular, anti-obesity and immuno-suppressant therapeutic areas.

 

  • Strong and diversified revenue streams

Revenue is diversified primarily across generics (27% of revenue in the first quarter of fiscal 2023), biosimilars (46%) and research services (30%), and intersegment revenue accounts for negative 3%.

 

The generics segment reported revenue growth in the first quarter of fiscal 2023, on low base of fiscal 2022 owing to the impact of Covid-19, driven by ramp up in API sales and healthy performance of recently launched formulations. Earlier, post a muted performance in the first half of last fiscal, the segment had witnessed recovery in the last quarter of fiscal 2022; its revenue in fiscal 2022 remained almost in line with last fiscal. Biocon has consolidated its position in this segment through its portfolio of differentiated APIs, including fermentation based, synthetic, high potent and peptides as well as vertically integrated complex formulations and a moderate growth is expected in this segment over medium term.

 

Biocon’s long-term growth potential will be led by its biosimilar and novel biologics segments in semi-regulated and regulated markets. While these segments continue to require large investment for R&D and capital expenditure (capex), the company is supported by steady cash flow from all its established business segments – generics, biosimilars and research services. As on June 30, 2022, the company had five approved biosimilar products in Europe and three in the US in partnership with Viatris Inc. Semglee® (biosimilar insulin glargine) was launched in the US in August 2020 and was Biocon’s third launch in that market after Fulphila® (biosimilar pegfilgrastin) and Ogivri® (biosimilar trastuzumab). Biocon received the European Commission’s approval for Abevmy® (biosimilar bevacizumab) and Kixelle® (biosimilar insulin aspart) in fiscal 2021. Furthermore, the United States Food and Drug Administration (US FDA) intimation is awaited for site inspection of facilities for the biosimilar bevacizumab. For biosimilar aspart, on-site pre-approval US FDA inspection for the company’s Malaysian facility was carried out in September 2021 and commercialisation should happen in due course. The company will continue to launch products in other key geographies.

 

Syngene International Ltd (Syngene, subsidiary of Biocon) enhances revenue diversity with sustained healthy growth and profitability. In fiscal 2022, Syngene accounted for one-third of the consolidated revenue and operating profit of Biocon. With commercialisation of the capex and ramp-up of operations, Syngene is expected to sustain its operating performance and revenue contribution over the medium term.

 

  • Healthy pipeline of biosimilar products

Biocon has strong R&D capability and several biosimilars and novel biologic products in development in the diabetes, oncology and autoimmune therapeutic segments. In partnership with Viatris Inc, Biocon’s biosimilar assets received approvals from various regulators and were launched in regulated and semi-regulated markets. Increase in the revenue and market share of key biosimilar assets (trastuzumab, pegfilgrastin and insulin glargine) in the US and Europe and successful launch of the biosimilars bevacizumab and insulin aspart will be key monitorables.

 

  • Strong financial risk profile

Adjusted gearing was healthy at ~0.6 time as on March 31, 2022. Interest coverage and net cash accrual to total debt ratios were healthy at 29.2 times and 0.3 time, respectively, in fiscal 2022. The company completed a series of fund-raising rounds at its subsidiary, BBL, in the past two fiscals and built up healthy cash and liquid investments of Rs 3,217 crore as on March 31, 2022, which will be utilised to partly fund capex and R&D. Biocon, BBL and Syngene are expected to undertake large annual capex of USD 80-100 million each over the medium term. Biocon is planning to operationalise its immunosuppressants and API facilities; BBL will undertake capex for commercialising a monoclonal antibodies facility and towards R&D for building a product pipeline. Syngene will increase capacity of its research and API manufacturing facilities. Because of consolidated net cash accrual of over Rs 2,000 crore per fiscal, strong liquidity and part funding of capex in biosimilars by Viatris Inc, the financial risk profile will remain healthy over the medium term. Debt protection metrics will nevertheless, moderate due to sizable debt addition by BBL to fund the proposed acquisition of the biosimilar business of Viatris. For instance, the debt to earnings before interest, tax, depreciation and amortisation (EBITDA) is seen moderating to 3.5-4 times in fiscal 2023 (from 2-2.5 times in fiscal 2022), before correcting back to 2-2.5 times in fiscal 2024.

 

Weaknesses

  • Uncertainty regarding payoffs in the R&D-driven model in biosimilars and novel biologic segments, especially for regulated markets

The company will continue to spend extensively on R&D for developing new molecules and biosimilars, particularly for the US and Europe. It remains vulnerable to long gestation period and uncertainty regarding timing and return on investments on new molecules, given the nature of the drug discovery model. Gross R&D and net R&D (net of capitalisation) were 15% and 13%, respectively, of the operating revenue, excluding Syngene, in the first quarter of fiscal 2023 (13% and 11%, respectively, in fiscal 2022). The R&D expenditure will increase over the medium term driven by expenses on clinical trials and R&D to build a robust product pipeline. The uncertainty regarding revenue visibility and return on the R&D expense expose the company to investment risk. However, it has achieved critical milestones in previous fiscals with approvals for biosimilars and launch in regulated and semi-regulated markets in partnership with Viatris Inc, leading to strong revenue growth. The extent of ramp up, particularly in the regulated markets, will be a key monitorable.

 

  • Susceptibility to regulatory uncertainties and intense competition

Regulatory risks are manifested in increasing scrutiny and inspections by regulatory authorities, including the US FDA, European Medical Agency and those in Asia and Latin America.

 

The company faces intense competition in regulated markets, which are characterised by aggressive defence tactics by innovator companies through introduction of authorised generics and the presence of several cost-competitive Indian players. In the branded formulations segment, additions to the list under Drug Price Control Order impact product pricing and profitability.

Liquidity: Strong

Expected cash accrual of over Rs 2,000 crore in fiscal 2023 will comfortably cover term debt obligation of around Rs 100 crore (including Syngene and BBL). Financial flexibility is high because of unencumbered cash and marketable securities of Rs 3,217 crore as on March 31, 2022. Biocon, BBL and Syngene are expected to undertake large annual capex of USD 80-100 million each over the medium term, which is likely to be funded through a prudent mix of cash accrual and debt. Liquidity may moderate should Biocon use the cash surplus to infuse funds into BBL for the acquisition of the biosimilars business of Viatris, but will remain healthy. Debt obligation will be sizeable over the medium term, post raising of loans by BBL, but will be serviced through accrual.

 

Environment, social, and governance (ESG) profile

CRISIL Ratings believes Biocon’s ESG profile supports its strong credit risk profile.

 

The pharmaceutical sector can have a significant impact on the environment on account of greenhouse gas emissions, water use and waste generation. The sector’s social impact is characterised by impact on the health and wellbeing of consumers on account of its products and on employees and local community on account of its operations.

 

Key ESG highlights

  • Biocon increased the share of green power in its total energy consumption by its Indian operations to over 58% in fiscal 2022. Company also achieved over 117,000 tonnes of carbon dioxide equivalent (tCO2) reductions during the year. Its Scope 1 and Scope 2 emissions increased marginally by 1% in fiscal 2022 on account of higher production.
  • The company has deployed water management practices and recycled 100% of wastewater in fiscal 2022. All manufacturing units are zero liquid discharge facilities.
  • It has implemented gender diversity and inclusion policy, human rights policy, suppliers code of conduct, prevention of sexual harassment policy as well as zero tolerance for child labour. Gender diversity in Biocon is in line with industry peers, with women employees comprising over 12% of the workforce.
  • Biocon’s corporate social responsibility is focused on primary healthcare, environmental sustainability, rural development and Covid-19 relief.
  • Biocon has adequate governance structure, with majority of its board comprising independent directors, presence of investor grievance redressal mechanism, whistle-blower policy and extensive disclosures.
  • Biocon also has board-level ESG committee to provide oversight, direction and to monitor the ESG strategy and action plans. 

There is growing importance of ESG among investors and lenders. Biocon’s continued commitment to ESG principles will play a key role in enhancing stakeholder confidence and ensure ease of raising capital from markets where ESG compliance is a key factor.

Rating Sensitivity factors

Upward factors

  • Significantly high revenue growth, driven by increased market share and improvement in profitability above 28%-30% on a sustained basis, leading to healthy annual cash accruals
  • Faster-than-anticipated improvement in debt protection metrics, post the acquisition of Viatris’ biosimilar business by BBL, supported by healthier accrual and equity raising at BBL

Downward factors

  • Decline in revenue growth and drop in operating margin to below 20% on a sustained basis
  • Delayed correction in debt protection metrics, due to further debt-funded capex or acquisitions or weaker cash generation; for instance, debt to earnings before interest, tax, depreciation and amortisation (EBITDA) ratio remaining above 2.5 times in fiscal 2024
  • Any adverse US FDA regulatory action materially impacting the operating performance

About the Company

Biocon, founded in 1978, is India’s leading biopharma company. It is fully integrated and delivers biopharma solutions, ranging from discovery to development and commercialisation. It has diversified revenue streams covering biologics (including branded formulations), contract research, and small molecules and APIs. As on June 30, 2022, the promoters held 60.64% stake in Biocon, foreign portfolio investors held 16.31%, and the balance was held by the public and others.

Key Financial Indicators

As on / for the period ended March 31   2022 2021
Revenue Rs crore 8184 7106
Adjusted profit after tax (PAT)* Rs crore 772 846
Adjusted PAT margin % 7.8 10.1
Adjusted debt / adjusted networth Times 0.55 0.56
Adjusted interest coverage Times 32.3 30.1

*Adjusted for amortisation of goodwill and intangibles

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of allotment

Coupon rate (%)

Maturity date

Issue size

(Rs crore)

Complexity

level

Rating assigned

with outlook

NA

Working capital facility

NA

NA

NA

100.0

NA

CRISIL AA+/Watch Developing

NA

Proposed working capital facility

NA

NA

NA

148.0

NA

CRISIL AA+/Watch Developing

NA

Proposed short-term bank loan facility

NA

NA

NA

2.0

NA

CRISIL A1+

Annexure – List of entities consolidated

Names of entities consolidated

Extent of consolidation

Rationale for consolidation

Syngene International Ltd

70.2%

Subsidiary

Biocon Biologics Ltd

93.5%

Subsidiary

Biocon Pharma Ltd

100.0%

Subsidiary

Biocon Academy

100.0%

Subsidiary

Biocon SA

100.0%

Subsidiary

Biocon SDN. BDH

93.5%

Step-down subsidiary

Biocon FZ LLC

100.0%

Subsidiary

Biocon Biologics UK Ltd

93.5%

Step-down subsidiary

Biocon Pharma Inc

100.0%

Step-down subsidiary

Biocon Biologics Healthcare SDN BHD

93.5%

Step-down subsidiary

Biocon Pharma Ireland Ltd

100.0%

Step-down subsidiary

Biocon Pharma UK Ltd

100.0%

Step-down subsidiary

Biocon Biosphere Ltd

100.0%

Subsidiary

Biocon Biologics Inc

93.5%

Step-down subsidiary

Biocon Biologics Do Brasil Ltda

93.5%

Step-down subsidiary

Biocon Biologics FZ-LLC

93.5%

Step-down subsidiary

Biocon Pharma Malta Ltd

100.0%

Step-down subsidiary

Biocon Pharma Malta I Ltd

100.0%

Step-down subsidiary

Biofusion Therapeutics Ltd

100.0%

Subsidiary

Syngene USA Inc

70.2%

Step-down subsidiary

Bicara Therapeutics Inc (up to January 9, 2021)

87.0%

Associate

Neo Biocon FZ-LLC

49.0%

Joint venture

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT/ST 250.0 CRISIL AA+/Watch Developing / CRISIL A1+ 07-06-22 CRISIL AA+/Watch Developing / CRISIL A1+ 30-09-21 CRISIL AA+/Stable / CRISIL A1+ 07-07-20 CRISIL AA+/Stable / CRISIL A1+ 29-06-19 CRISIL AA+/Stable / CRISIL A1+ CRISIL AA+/Stable / CRISIL A1+
      -- 09-03-22 CRISIL AA+/Watch Developing / CRISIL A1+   --   --   -- --
      -- 11-02-22 CRISIL AA+/Stable / CRISIL A1+   --   --   -- --
Short Term Debt ST   --   --   --   -- 29-06-19 Withdrawn CRISIL A1+
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Proposed Short Term Bank Loan Facility 2 - CRISIL A1+
Proposed Working Capital Facility 148 - CRISIL AA+/Watch Developing
Working Capital Facility 100 HDFC Bank Limited CRISIL AA+/Watch Developing
Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
CRISILs Criteria for Consolidation
Understanding CRISILs Ratings and Rating Scales

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Anuj Sethi
Senior Director
CRISIL Ratings Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Aditya Jhaver
Director
CRISIL Ratings Limited
B:+91 22 3342 3000
Aditya.Jhaver@crisil.com


Parth Shah
Manager
CRISIL Ratings Limited
B:+91 22 3342 3000
Parth.Shah@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL’s privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale (‘report’) that is provided by CRISIL Ratings Limited (‘CRISIL Ratings’). To avoid doubt, the term ‘report’ includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, ‘CRISIL Ratings Parties’) guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html